Nonserious infections (NSIE) as colds, flu syndromes, and urinary tract infection, are the most common infections seen in patients with immune mediated inflammatory diseases. Yet, little is known about the impact of immunosuppression, particularly with tumor necrosis factor inhibitors (TNFi), on these infections. A systemic review of large, randomized controlled trials was conducted to identify incidence, types, and outcomes of NSIE associated with the most commonly prescribed TNFi: adalimumab, etanercept, and infliximab.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.rdc.2012.08.016 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!